Orizolin (Powder) Instructions for Use
Marketing Authorization Holder
Cadila Healthcare Ltd. (India)
ATC Code
J01DB04 (Cefazolin)
Active Substance
Cefazolin (Rec.INN registered by WHO)
Dosage Form
| Orizolin | Powder for solution for intravenous and intramuscular administration 1 g: vial. 1 pc. |
Dosage Form, Packaging, and Composition
| Powder for solution for intravenous and intramuscular administration | 1 vial |
| Cefazolin sodium | 1 g |
1 g – vials (1) – cardboard packs.
Clinical-Pharmacological Group
First generation cephalosporin
Pharmacotherapeutic Group
Antibiotic-cephalosporin
Pharmacological Action
Cephalosporin antibiotic of the first generation with a broad spectrum of action. It has a bactericidal effect.
It is active against gram-positive bacteria: Staphylococcus spp. (strains producing and not producing penicillinase), Streptococcus spp. (including Streptococcus pneumoniae), Corynebacterium diphtheriae, Bacillus anthracis; gram-negative bacteria: Neisseria meningitidis, Neisseria gonorrhoeae, Shigella spp., Salmonella spp., Escherichia coli, Klebsiella spp.
It is also active against Spirochaetoceae, Leptospira spp.
It is not active against Pseudomonas aeruginosa, indole-positive strains of Proteus spp., Mycobacterium tuberculosis, anaerobic bacteria.
Pharmacokinetics
Cefazolin is poorly absorbed from the gastrointestinal tract and is therefore administered intramuscularly or intravenously. After intramuscular administration of a 500 mg dose, the Cmax in plasma is reached in 1-2 hours and is 30 µg/ml.
Plasma protein binding is about 85%.
Cefazolin penetrates into bone tissue, ascitic fluid, pleural and synovial fluids, but is not detected in the CNS.
The T1/2 of cefazolin from plasma is about 1.8 hours.
Cefazolin is excreted in the urine unchanged, mainly by glomerular filtration and to a small extent by tubular secretion. After intramuscular administration, at least 80% of the dose is excreted within 24 hours. After intramuscular administration of 500 mg and 1 g doses, the Cmax in urine is 1 mg/ml and 4 mg/ml, respectively.
There is evidence of high concentrations of cefazolin in bile, although it is excreted by this route in small amounts.
The T1/2 from plasma is increased in patients with impaired renal function.
Indications
Infectious and inflammatory diseases caused by microorganisms sensitive to cefazolin, including diseases of the upper and lower respiratory tract, urinary and biliary tract, pelvic organs, skin and soft tissues, bones and joints, endocarditis, sepsis, peritonitis, otitis media, osteomyelitis, mastitis, wound, burn and postoperative infections, syphilis, gonorrhea.
ICD codes
| ICD-10 code | Indication |
| A40 | Streptococcal sepsis |
| A41 | Other sepsis |
| A50 | Congenital syphilis |
| A51 | Early syphilis |
| A52 | Late syphilis |
| A54 | Gonococcal infection |
| H66 | Suppurative and unspecified otitis media |
| I33 | Acute and subacute endocarditis |
| J00 | Acute nasopharyngitis (common cold) |
| J01 | Acute sinusitis |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04 | Acute laryngitis and tracheitis |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J20 | Acute bronchitis |
| J31.2 | Chronic pharyngitis |
| J32 | Chronic sinusitis |
| J35.0 | Chronic tonsillitis |
| J37 | Chronic laryngitis and laryngotracheitis |
| J42 | Unspecified chronic bronchitis |
| K65.0 | Acute peritonitis (including abscess) |
| K81.0 | Acute cholecystitis |
| K81.1 | Chronic cholecystitis |
| K83.0 | Cholangitis |
| L01 | Impetigo |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L03 | Cellulitis |
| L08.0 | Pyoderma |
| L08.8 | Other specified local infections of skin and subcutaneous tissue |
| M00 | Pyogenic arthritis |
| M86 | Osteomyelitis |
| N10 | Acute tubulointerstitial nephritis (acute pyelonephritis) |
| N11 | Chronic tubulointerstitial nephritis (chronic pyelonephritis) |
| N30 | Cystitis |
| N34 | Urethritis and urethral syndrome |
| N37.0 | Urethritis in diseases classified elsewhere |
| N41 | Inflammatory diseases of prostate |
| N61 | Inflammatory diseases of the breast |
| N70 | Salpingitis and oophoritis |
| N71 | Inflammatory disease of uterus, excluding cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess) |
| N72 | Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis) |
| N73.5 | Unspecified female pelvic peritonitis |
| N74.3 | Gonococcal inflammatory diseases of female pelvic organs |
| T30 | Burns and corrosions of unspecified body region |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| ICD-11 code | Indication |
| 1A60.Z | Congenital syphilis, unspecified |
| 1A61.Z | Early syphilis, unspecified |
| 1A62.Z | Late syphilis, unspecified |
| 1A7Z | Gonococcal infection, unspecified |
| 1B70.1 | Streptococcal cellulitis of the skin |
| 1B70.2 | Staphylococcal cellulitis of the skin |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B72.0 | Bullous impetigo |
| 1B72.1 | Nonbullous impetigo |
| 1B72.Z | Impetigo, unspecified |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1B7Y | Other specified pyogenic bacterial infections of skin or subcutaneous tissue |
| 1C44 | Non-pyogenic bacterial infections of skin |
| 1G40 | Sepsis without septic shock |
| AA9Z | Unspecified suppurative otitis media |
| BB4Z | Acute or subacute endocarditis, unspecified |
| CA00 | Acute nasopharyngitis |
| CA01 | Acute rhinosinusitis |
| CA02.Z | Acute pharyngitis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA05 | Acute laryngitis or tracheitis |
| CA09.2 | Chronic pharyngitis |
| CA0A.Z | Chronic rhinosinusitis, unspecified |
| CA0F.Y | Other specified chronic diseases of the palatine tonsils and adenoids |
| CA0G | Chronic laryngitis or laryngotracheitis |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| DC12.0Z | Acute cholecystitis, unspecified |
| DC12.1 | Chronic cholecystitis |
| DC13 | Cholangitis |
| DC50.0 | Primary peritonitis |
| DC50.2 | Peritoneal abscess |
| DC50.Z | Peritonitis, unspecified |
| EA50.3 | Staphylococcal scarlet fever |
| EB21 | Pyoderma gangrenosum |
| FA1Z | Infectious arthropathies, unspecified |
| FB84.Z | Osteomyelitis or osteitis, unspecified |
| GA01.Z | Inflammatory diseases of uterus, except cervix, unspecified |
| GA05.2 | Unspecified pelvic peritonitis in women |
| GA07.Z | Salpingitis and oophoritis, unspecified |
| GA91.Z | Inflammatory and other diseases of prostate, unspecified |
| GB21.Z | Inflammatory diseases of the breast, unspecified |
| GB50 | Acute tubulo-interstitial nephritis |
| GB51 | Acute pyelonephritis |
| GB55.Z | Chronic tubulo-interstitial nephritis, unspecified |
| GB5Z | Renal tubulo-interstitial diseases, unspecified |
| GC00.Z | Cystitis, unspecified |
| GC02.1 | Nonspecific urethritis |
| GC02.Z | Urethritis and urethral syndrome, unspecified |
| NE11 | Burn of unspecified body region |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
| 1A71 | Gonococcal pelviperitonitis |
| GA05.Z | Inflammatory diseases of female pelvic organs, unspecified |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| XA5WW1 | Cervix uteri |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
The dosage is set individually, taking into account the severity and localization of the infection, and the sensitivity of the pathogen.
It is administered intramuscularly or intravenously (bolus or drip). The average daily dose for adults is 1 g, the frequency of administration is 2-4 times/day.
For the prevention of postoperative infection, it is administered at a dose of 1 g 30 minutes before surgery, 0.5-1 g during surgery, and 0.5-1 g every 6-8 hours for 24 hours after surgery.
Maximum dose 6 g/day.
For children, the average daily dose is 20-40 mg/kg; in severe infections, the dose can be increased to 100 mg/kg/day. The duration of treatment is 7-10 days.
Adverse Reactions
From the digestive system nausea, vomiting, diarrhea are possible; rarely – a transient increase in the activity of hepatic transaminases.
Allergic reactions urticaria, skin itching, eosinophilia, fever are possible; in isolated cases – angioedema, arthralgia, anaphylactic shock.
Effects due to chemotherapeutic action candidiasis, pseudomembranous colitis.
From the hematopoietic system rarely – reversible leukopenia, neutropenia, thrombocytopenia.
From the urinary system rarely – impaired renal function.
Local reactions pain at the intramuscular injection site is possible.
Contraindications
Children under 1 month of age, hypersensitivity to cephalosporins.
Use in Pregnancy and Lactation
It crosses the placental barrier.
Low concentrations of cefazolin are detected in breast milk.
Use during pregnancy and lactation is justified only in cases where the expected benefit to the mother outweighs the potential risk to the fetus or child.
Use in Renal Impairment
Use with caution in patients with impaired renal function.
Pediatric Use
Contraindicated in children under 1 month of age.
Use in children over 1 month of age is possible according to the dosage regimen.
Special Precautions
Use with caution in patients with impaired renal function.
In patients with hypersensitivity to penicillins, allergic reactions to cephalosporin antibiotics are possible.
During treatment, a false-positive urine reaction for sugar is possible.
Cefazolin is removed by hemodialysis.
Drug Interactions
With simultaneous use with “loop” diuretics, tubular secretion of cefazolin is blocked (such a combination is not recommended).
Cefazolin can cause disulfiram-like reactions when used simultaneously with ethanol.
Probenecid impairs the excretion of cefazolin.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer